A/Prof Michael Woodward AM
Videos iconVideos

In this Product Explainer Geriatrician A/Prof Michael Woodward AM explains an adjuvanted vaccine indicated for the active immunisation of individuals 60 years and older for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).1

A/Prof Christopher Blyth
Clinical Articles iconClinical Articles

All WA babies under eight months old, as well as those aged eight to 19 months at increased risk of severe RSV infection, will be eligible for monoclonal antibodies.

Dr Monica Wang
Clinical Articles iconClinical Articles

The global anti-vaccine movement and vaccine hesitancy that accelerated during the COVID-19 pandemic show no signs of abating...

Expert/s: Dr Monica Wang
Lynnette Hoffman
Clinical Articles iconClinical Articles

What we know about the RSV vaccines so far...

Prof Paul Van Buynder
Videos iconVideos

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Healthed Logo
Learning Modules iconLearning Modules

The 2023 influenza season is expected to start early and be more severe than the last few years. It’s important for front line immunisers to be updated with the latest information, public health advice and practical strategies for this year’s season. Influenza causes a large burden of disease in Australia with sick days, hospitalisation and death. Vaccination is readily available and updated yearly to include the most recent strains. It is widely recommended across the community, but especially for the most vulnerable including the very young, old, Indigenous Australians, and people with underlying comorbidities.

Prof Paul Griffin
Videos iconVideos

In this Product Explainer, Infectious Disease Physician and Clinical Microbiologist A/Prof Paul Griffin explains the recombinant protein nanoparticle COVID-19 vaccine with a proprietary adjuvant, including the mechanism of action, efficacy, and tolerability; and provides an update on boosters, indications, and access (8 mins).

A/Prof John Litt AM
Videos iconVideos

In this Product Explainer, Public Health Physician A/Prof John Litt AM explains the currently funded adjuvanted quadrivalent influenza vaccine for people 65 years and over and how it fits in the 2023 influenza season (6 mins). This product explainer is supported by Seqirus

Emma Tinning
Clinical Articles iconClinical Articles

Meningococcal B strain is responsible for most recent cases in NSW, but free access to that vaccine is limited

Expert/s: Emma Tinning
Dr Daryl Cheng
Videos iconVideos

In this Product Explainer, Paediatrician Dr Daryl Cheng explains the role of the MenACWY-TT conjugate vaccine for invasive meningococcal disease, the importance of adolescent vaccination and opportunistic immunisation, and the healthcare professional’s role in improving uptake rates in this age group (7 mins).

PP-NIM-AUS-0340. May 2023

Expert/s: Dr Daryl Cheng
Prof Paul Van Buynder
Videos iconVideos

In this Product Explainer, Public Health Physician Prof Paul Van Buynder explains the role of the Bivalent Original/Omicron BA.4-5 pre-filled syringe COVID-19 vaccine and provides an update on the situation in aged care, and how boosters can assist in protecting the community against symptomatic infection and severe disease (5 mins).

Prof Nancy Baxter
Podcasts iconPodcasts

Why there is increasingly conflicting booster advice emerging from different parts of the world